person · Reporting owner

Horning Sandra

Disclosed activity across 5 companies

Tapewire entity: 14722
SEC CIK: 0001638709

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GILEAD SCIENCES, INC.GILD · Entity 405	Director	April 30, 2026	May 04, 2026
Moderna, Inc.MRNA · Entity 2025	Director	May 06, 2026	May 08, 2026
Olema Pharmaceuticals, Inc.OLMA · Entity 613	Director	June 18, 2026	June 23, 2026
Revolution Medicines, Inc.RVMD · Entity 606	Director	June 18, 2026	June 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GILEAD SCIENCES, INC.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,293	Reported balance After 2026-04-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-04-30 · Grant · Acquired 1,146 · Balance 6,293 F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $130.84 · Expires 2036-04-30	Direct	4,884	Reported balance After 2026-04-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-30 · Grant · Acquired 4,884 · Balance 4,884 F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Moderna, Inc.

Report date May 06, 2026 · Filed May 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.79 · Expires 2036-05-06	Direct	9,681	Reported balance After 2026-05-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-06 · Grant · Acquired 9,681 · Balance 9,681 F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,092	Reported balance After 2026-05-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-06 · Grant · Acquired 2,092 · Balance 2,092 F2: Restricted stock units convert into common stock on a one-for-one basis. F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.

Olema Pharmaceuticals, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2036-06-18	Direct	29,500	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 29,500 · Balance 29,500 F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Revolution Medicines, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	97,765	Reported balance After 2026-06-18 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 1,191 · Balance 97,765 F1: Includes 6,083 restricted stock units.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $162.99 · Expires 2036-06-18	Direct	3,127	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Grant · Acquired 3,127 · Balance 3,127 F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 6,083 restricted stock units.

F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

EQRx, Inc.

Report date November 09, 2023 · Filed November 09, 2023

Section 16 reporting ended · disclosed 2023-11-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-09 transaction · row 1 1 source row Row 1 · 2023-11-09 · Disposition to issuer · Disposed 470,250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2030-08-21	Direct	Reported balance After 2023-11-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-11-09 · Disposition to issuer · Disposed 313,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.95 · Expires 2032-09-30	Direct	Reported balance After 2023-11-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-11-09 · Disposition to issuer · Disposed 101,010 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	Direct	Reported balance After 2023-11-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-09 · Disposition to issuer · Disposed 107,929 · Balance 0 F5: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 107,929 shares of Issuer common stock (the "Earn-out Shares"), (i) 75,550 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,379 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. F6: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F7: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time.

F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).

F5: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 107,929 shares of Issuer common stock (the "Earn-out Shares"), (i) 75,550 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,379 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50.

F6: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement.

F7: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 18, 2026 Filed Jun 23, 2026 21:45 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	3,127	$0.00 Strike: $162.99	$0.00	Disclosure SEC source: 0001610717-26-000286 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,127 Underlying: Common Stock · 3,127 shares Expires 2036-06-18 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:45 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	1,191	$0.00	$0.00	Disclosure SEC source: 0001610717-26-000286 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,765 F1 · balance_after: Includes 6,083 restricted stock units. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:24 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	29,500	$0.00 Strike: $9.51	$0.00	Disclosure SEC source: 0001638709-26-000004 · form4-06232026_090644.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 29,500 shares Expires 2036-06-18 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
May 06, 2026 Filed May 8, 2026 21:04 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	2,092	$0.00	$0.00	Disclosure SEC source: 0001682852-26-000093 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,092 Underlying: Common Stock · 2,092 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document
May 06, 2026 Filed May 8, 2026 21:04 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	9,681	$0.00 Strike: $48.79	$0.00	Disclosure SEC source: 0001682852-26-000093 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,681 Underlying: Common Stock · 9,681 shares Expires 2036-05-06 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document
April 30, 2026 Filed May 4, 2026 21:39 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionRestricted Stock Units · Derivative	16,233	$0.00	$0.00	Disclosure SEC source: 0001682852-26-000075 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. Read SEC document
April 30, 2026 Filed May 4, 2026 21:39 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionCommon Stock	16,233	Not disclosed	Not disclosed	Disclosure SEC source: 0001682852-26-000075 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
April 30, 2026 Filed May 4, 2026 20:31 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	4,884	$0.00 Strike: $130.84	$0.00	Disclosure SEC source: 0001638709-26-000002 · wk-form4_1777926706.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,884 Underlying: Common Stock · 4,884 shares Expires 2036-04-30 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026. Read SEC document
April 30, 2026 Filed May 4, 2026 20:31 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	1,146	$0.00	$0.00	Disclosure SEC source: 0001638709-26-000002 · wk-form4_1777926706.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,293 F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. Read SEC document
June 26, 2025 Filed Jun 30, 2025 20:27 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	11,574	$0.00 Strike: $37.48	$0.00	Disclosure SEC source: 0001610717-25-000273 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,574 Underlying: Common Stock · 11,574 shares Expires 2035-06-26 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 26, 2025 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document
June 26, 2025 Filed Jun 30, 2025 20:27 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	3,142	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000273 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,574 F1 · balance_after: Includes 8,392 Restricted Stock Units. Read SEC document
June 11, 2025 Filed Jun 13, 2025 21:00 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	24,150	$0.00 Strike: $4.08	$0.00	Disclosure SEC source: 0001415889-25-017238 · form4-06132025_050624.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,150 Underlying: Common Stock · 24,150 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
May 07, 2025 Filed May 9, 2025 00:26 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	6,809	$0.00 Strike: $98.90	$0.00	Disclosure SEC source: 0001127602-25-013774 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,809 Underlying: Common Stock · 6,809 shares Expires 2035-05-07 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 7, 2025. Read SEC document
May 07, 2025 Filed May 9, 2025 00:26 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	1,516	$0.00	$0.00	Disclosure SEC source: 0001127602-25-013774 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,147 F1 · security: Represents 1,516 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 7, 2025. Read SEC document
April 30, 2025 Filed May 1, 2025 20:28 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	16,233	$0.00	$0.00	Disclosure SEC source: 0001127602-25-012934 · form4.xml · derivative · entry 3 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,233 Underlying: Common Stock · 16,233 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document
April 30, 2025 Filed May 1, 2025 20:28 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionRestricted Stock Units · Derivative	979	$0.00	$0.00	Disclosure SEC source: 0001127602-25-012934 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 30, 2025. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 30, 2025. Read SEC document
April 30, 2025 Filed May 1, 2025 20:28 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionCommon Stock	979	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-012934 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 20, 2024 Filed Jun 24, 2024 20:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	16,700	$0.00 Strike: $37.54	$0.00	Disclosure SEC source: 0001610717-24-000362 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,700 Underlying: Common Stock · 16,700 shares Expires 2034-06-19 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document
June 20, 2024 Filed Jun 24, 2024 20:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	4,800	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000362 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,287 F1 · balance_after: Includes 13,550 Restricted Stock Units. Read SEC document
June 20, 2024 Filed Jun 28, 2024 21:05 UTC Amendment	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	10,248	$0.00 Strike: $37.54	$0.00	Disclosure SEC source: 0001610717-24-000373 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,248 Underlying: Common Stock · 10,248 shares Expires 2034-06-19 F2 · derivative.exercise_date: Shares subject to the Stock Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Issuer's annual meeting of stockholders following the date of grant, subject to the Reporting Person continuing in service through the vesting date. Read SEC document
June 20, 2024 Filed Jun 28, 2024 21:05 UTC Amendment	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	2,945	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000373 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,432 F1 · balance_after: Includes 11,695 restricted stock units ("RSUs"). Read SEC document
June 14, 2024 Filed Jun 18, 2024 21:00 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	23,000	$0.00 Strike: $12.36	$0.00	Disclosure SEC source: 0001415889-24-017444 · form4-06182024_050611.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
May 08, 2024 Filed May 9, 2024 19:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	12,648	$0.00 Strike: $64.92	$0.00	Disclosure SEC source: 0001127602-24-014767 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,648 Underlying: Common Stock · 12,648 shares Expires 2034-05-08 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024. Read SEC document
May 08, 2024 Filed May 9, 2024 19:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantRestricted Stock Unit · Derivative	2,310	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-014767 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,801 Underlying: Common Stock · 2,310 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024. F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024. Read SEC document
May 06, 2024 Filed May 7, 2024 20:54 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	979	$0.00	$0.00	Disclosure SEC source: 0001127602-24-014466 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 979 Underlying: Common Stock · 979 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
May 06, 2024 Filed May 7, 2024 20:54 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	5,668	$0.00 Strike: $122.13	$0.00	Disclosure SEC source: 0001127602-24-014466 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,668 Underlying: Common Stock · 5,668 shares Expires 2034-05-06 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
November 09, 2023 Filed Nov 9, 2023 16:13 UTC	EQRx, Inc. EQRX · Entity 108311	Disposition to issuerEarn-out Shares · Derivative	107,929	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-020303 · doc4.xml · derivative · entry 4 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,929 shares Expires 2024-12-17 F5 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 107,929 shares of Issuer common stock (the "Earn-out Shares"), (i) 75,550 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,379 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. F6 · derivative.exercise_price: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement. F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F5 · price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 107,929 shares of Issuer common stock (the "Earn-out Shares"), (i) 75,550 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,379 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. F6 · price: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement. F2 · derivative.exercise_date: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F7 · derivative.exercise_date: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement. Read SEC document
November 09, 2023 Filed Nov 9, 2023 16:13 UTC	EQRx, Inc. EQRX · Entity 108311	Disposition to issuerStock Option (Right to Buy) · Derivative	101,010	$0.00 Strike: $4.95	$0.00	Disclosure SEC source: 0000899243-23-020303 · doc4.xml · derivative · entry 3 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,010 shares Expires 2032-09-30 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4 · derivative.exercise_date: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration). Read SEC document
November 09, 2023 Filed Nov 9, 2023 16:13 UTC	EQRx, Inc. EQRX · Entity 108311	Disposition to issuerStock Option (Right to Buy) · Derivative	313,500	$0.00 Strike: $0.44	$0.00	Disclosure SEC source: 0000899243-23-020303 · doc4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 313,500 shares Expires 2030-08-21 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4 · derivative.exercise_date: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration). Read SEC document
November 09, 2023 Filed Nov 9, 2023 16:13 UTC	EQRx, Inc. EQRX · Entity 108311	Disposition to issuerCommon Stock	470,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-020303 · doc4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2 · price: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. Read SEC document
November 09, 2023 Filed Nov 15, 2023 01:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	36,800	$0.00 Strike: $20.02	$0.00	Disclosure SEC source: 0001610717-23-000356 · form4.xml · derivative · entry 5 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,800 Underlying: Common Stock · 36,800 shares Expires 2033-11-08 F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of November 8, 2023, subject to the reporting person's continued employment or service relationship with the Company on each such vesting date. Read SEC document
November 09, 2023 Filed Nov 15, 2023 01:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantEarn-out Shares · Derivative	10,651	Not disclosed	Not disclosed	Disclosure SEC source: 0001610717-23-000356 · form4.xml · derivative · entry 4 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,651 Underlying: Common Stock · 10,651 shares Expires 2024-12-17 F4 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares. F4 · price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares. F4 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares. Read SEC document
November 09, 2023 Filed Nov 15, 2023 01:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	10,500	$0.00	$0.00	Disclosure SEC source: 0001610717-23-000356 · form4.xml · nonDerivative · entry 3 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,487 F3 · balance_after: Includes 10,500 restricted stock units. Read SEC document
November 09, 2023 Filed Nov 15, 2023 01:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	27,696	Not disclosed	Not disclosed	Disclosure SEC source: 0001610717-23-000356 · form4.xml · nonDerivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,987 F2 · shares: Pursuant to the Merger Agreement, at the Effective Time, a stock option to purchase shares of EQRx, Inc. common stock that was outstanding immediately prior to the Effective Time was cancelled and converted automatically into the right to receive 27,696 shares of the Company's common stock. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, a stock option to purchase shares of EQRx, Inc. common stock that was outstanding immediately prior to the Effective Time was cancelled and converted automatically into the right to receive 27,696 shares of the Company's common stock. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. Read SEC document
November 09, 2023 Filed Nov 15, 2023 01:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	52,291	Not disclosed	Not disclosed	Disclosure SEC source: 0001610717-23-000356 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,291 F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. Read SEC document
June 16, 2023 Filed Jun 21, 2023 21:00 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	21,520	$0.00 Strike: $7.84	$0.00	Disclosure SEC source: 0001415889-23-010105 · form4-06212023_050618.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2033-06-15 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
May 03, 2023 Filed May 5, 2023 20:11 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	6,134	$0.00 Strike: $130.14	$0.00	Disclosure SEC source: 0001127602-23-014677 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,134 Underlying: Common Stock · 6,134 shares Expires 2033-05-03 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
May 03, 2023 Filed May 4, 2023 22:02 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	10,173	$79.45 Strike: $79.45	$808,244.85	Disclosure SEC source: 0001127602-23-014558 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,173 Underlying: Common Stock · 10,173 shares Expires 2033-05-03 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023. Read SEC document
May 03, 2023 Filed May 4, 2023 22:02 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	1,887	$0.00	$0.00	Disclosure SEC source: 0001127602-23-014558 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,631 F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023. Read SEC document
April 28, 2023 Filed May 1, 2023 21:35 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionRestricted Stock Units · Derivative	670	$0.00	$0.00	Disclosure SEC source: 0001127602-23-013922 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 670 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 28, 2023. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 28, 2023. Read SEC document
April 28, 2023 Filed May 1, 2023 21:35 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionCommon Stock	670	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-013922 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 01, 2023 Filed Jan 4, 2023 21:55 UTC	EQRx, Inc. EQRX · Entity 108311	GrantEarn-out Shares · Derivative	565	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-001114 · tm231679-10_4seq1.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,929 Underlying: Common Stock · 565 shares Expires 2024-12-17 F1 · derivative.exercise_price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 565 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 395 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 170 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · kind: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 565 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 395 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 170 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 565 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 395 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 170 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · derivative.exercise_date: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 565 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 395 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 170 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). Read SEC document
September 30, 2022 Filed Oct 4, 2022 20:29 UTC	EQRx, Inc. EQRX · Entity 108311	GrantStock Option (Right to Buy) · Derivative	101,010	$0.00 Strike: $4.95	$0.00	Disclosure SEC source: 0001104659-22-106023 · tm2227449-6_4seq1.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,010 Underlying: Common Stock · 101,010 shares Expires 2032-09-30 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan). Read SEC document
June 17, 2022 Filed Jun 27, 2022 21:15 UTC Amendment	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	21,520	$0.00 Strike: $3.61	$0.00	Disclosure SEC source: 0001415889-22-006964 · form4a-06272022_020650.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2032-06-16 F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein. F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein. F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
June 16, 2022 Filed Jun 17, 2022 23:30 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	21,520	$0.00 Strike: $3.43	$0.00	Disclosure SEC source: 0001415889-22-006786 · form4-06172022_040650.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2032-06-15 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
May 05, 2022 Filed May 6, 2022 22:29 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	15,851	$61.35 Strike: $61.35	$972,458.85	Disclosure SEC source: 0001127602-22-013715 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document
May 05, 2022 Filed May 6, 2022 22:29 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantRestricted Stock Unit · Derivative	2,444	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-013715 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,491 Underlying: Common Stock · 2,444 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 5, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 5, 2022. Read SEC document
May 03, 2022 Filed May 4, 2022 00:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionRestricted Stock Unit · Derivative	1,112	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-013127 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,047 Underlying: Common Stock · 1,112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document
May 03, 2022 Filed May 4, 2022 00:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	1,112	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-013127 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. Read SEC document
April 28, 2022 Filed May 2, 2022 20:38 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	670	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-22-012854 · form4.xml · derivative · entry 4 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670 Underlying: Common Stock · 670 shares Expires not disclosed F4 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F4 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.